LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (Nasdaq: SVA).
If you purchased or otherwise acquired Sinovac shares, and would like more information about the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you.
The investigation focuses on whether Sinovac and certain of its officers and/or directors violated federal securities laws. On December 21, 2016, SeekingAlpha.com published an article revealing that the Company’s Chairman and CEO Weidong Ying paid bribes to the Deputy Director General of the Center for Drug Evaluation for the China Food and Drug Administration and his wife, in order to help advance drug applications and evaluations. On May 16, 2017, Sinovac announced that the U.S. Securities & Exchange Commission is conducting an enforcement investigation related to the bribery discussed in the article, and that the Company would not be able to timely file its annual financial results.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.
Goldberg Law PC represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.